. 2013 Sep 2;6(5):1251–1258. doi: 10.3892/etm.2013.1284

Table II.

Effects of NGF on the levels of IL-4 and IL-13 in the BALF and serum levels of OVA-specific IgE.

Group	BALF (pg/ml)		Serum (μg/ml) OVA-specific IgE
Group	IL-4	IL-13	Serum (μg/ml) OVA-specific IgE
Control	21.25±2.78	71.50±3.79	-
OVA	66.00±2.27^a	132.50±4.64^a	11.15±0.43^a
NGF	82.50±4.05^b	149.75±3.12^b	14.98±0.73^c
Anti-NGF	51.00±3.02^b	90.75±2.32^c	5.63±0.46^c

Treatment with NGF increased the levels of the Th2 cytokines IL-4 and IL-13 in the BALF and the total serum levels of IgE in the rat model of chronic asthma. However, administration of anti-NGF reduced the levels of IL-4 and -13 in the BALF and total serum IgE. Values are expressed as the mean ± standard error of the mean of 8 rats in each treatment group.

P<0.01 compared with the control group,

P<0.05 and

P<0.01 compared with the OVA group. NGF, nerve growth factor; IL, interleukin; BALF, bronchoalveolar lavage fluid; IgE, immunoglobulin E; OVA, ovalbumin.